Therapy for Recurrent High-Grade Gliomas: Does Continuous Dose-Intense Temozolomide Have a Role?

被引：10

作者：

Wen, Patrick Y. ^{[1
,2
]}

机构：

[1] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA

[2] Brigham & Womens Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 12期

关键词：

PHASE-II TRIAL; BEVACIZUMAB PLUS IRINOTECAN; MGMT PROMOTER METHYLATION; PROGRESSION-FREE SURVIVAL; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMAS; GLIOBLASTOMA; RADIOTHERAPY; CHEMOTHERAPY; CONCOMITANT;

D O I：

10.1200/JCO.2009.27.6014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1977 / 1979

页数：3

共 27 条

[1]

BRADA M, 2008, 33 M EUR SOC MED ONC

[2] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) [J].

Brandes, A. A. ;

Tosoni, A. ;

Cavallo, G. ;

Bertorelle, R. ;

Gioia, V. ;

Franceschi, E. ;

Biscuola, M. ;

Blatt, V. ;

Crino, L. ;

Ermani, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1155-1160

[3] Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J].

Brandsma, Dieto ;

Stalpers, Lukas ;

Taal, Walter ;

Sminia, Peter ;

van den Bent, Martinj .

LANCET ONCOLOGY, 2008, 9 (05) :453-461

[4] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].

Cairncross, Gregory ;

Berkey, Brian ;

Shaw, Edward ;

Jenkins, Robert ;

Scheithauer, Bernd ;

Brachman, David ;

Buckner, Jan ;

Fink, Karen ;

Souhami, Luis ;

Laperierre, Normand ;

Mehta, Minesh ;

Curran, Walter .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714

[5]

*CENTR BRAIN TUM R, 2008, STAT REP PRIM BRAIN

[6] Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma [J].

Chamberlain, Marc C. ;

Glantz, Michael J. ;

Chalmers, Lisa ;

Van Horn, Alixis ;

Sloan, Andrew E. .

JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (01) :81-83

[7] Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas [J].

Desjardins, Annick ;

Reardon, David A. ;

Herndon, James E., II ;

Marcello, Jennifer ;

Quinn, JenniferA. ;

Rich, Jeremy N. ;

Sathornsumetee, Sith ;

Gururangan, Sriclharan ;

Sampson, John ;

Bailey, Leighann ;

Bigner, Darell D. ;

Friedman, Allan H. ;

Friedman, Henry S. ;

Vredenburgh, James J. .

CLINICAL CANCER RESEARCH, 2008, 14 (21) :7068-7073

[8] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J].

Friedman, Henry S. ;

Prados, Michael D. ;

Wen, Patrick Y. ;

Mikkelsen, Tom ;

Schiff, David ;

Abrey, Lauren E. ;

Yung, W. K. Alfred ;

Paleologos, Nina ;

Nicholas, Martin K. ;

Jensen, Randy ;

Vredenburgh, James ;

Huang, Jane ;

Zheng, Maoxia ;

Cloughesy, Timothy .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4733-4740

[9] MGMT gene silencing and benefit from temozolomide in glioblastoma [J].

Hegi, ME ;

Diserens, A ;

Gorlia, T ;

Hamou, M ;

de Tribolet, N ;

Weller, M ;

Kros, JM ;

Hainfellner, JA ;

Mason, W ;

Mariani, L ;

Bromberg, JEC ;

Hau, P ;

Mirimanoff, RO ;

Cairncross, JG ;

Janzer, RC ;

Stupp, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003

[10] Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity [J].

Hegi, Monika E. ;

Liu, Lili ;

Herman, James G. ;

Stupp, Roger ;

Wick, Wolfgang ;

Weller, Michael ;

Mehta, Minesh P. ;

Gilbert, Mark R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4189-4199

← 1 2 3 →